Résultats de la recherche - Nikolay Conev
- Résultat(s) 1 - 7 résultats de 7
-
1
-
2
Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients par Nikolay Conev, Ivan Donev, Assia Konsoulova, Trifon Chervenkov, Yаvor Kashlov, Krasimir Ivanov
Publié 2015Artigo -
3
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer par Mila Petrova, Mariyana Eneva, Jeliazko Arabadjiev, Nikolay Conev, E Dimitrová, Krassimir Koynov, Teodora Karanikolova, Spartak Valev, Radostina Gencheva, Georgi Zhbantov, Anika Ivanova, Iva I. Sarbianova, Constanta Timcheva, Ivan Donev
Publié 2020Artigo -
4
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer par Nikolay Conev, E Dimitrová, Margarita K. Bogdanova, Yаvor Kashlov, Borislav Chaushev, Maria Radanova, Dilyan Petrov, Kaloyan Georgiev, Chavdar Bachvarov, G Todorov, Kalin Kalchev, Hristo Popov, Rostislav Manev, Ivan Donev
Publié 2019Artigo -
5
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report par Yuanbin Chen, Luis Paz‐Ares, Niels Reinmuth, Marina Chiara Garassino, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Francesco Verderame, Libor Havel, György Losonczy, Nikolay Conev, Katsuyuki Hotta, Jun Ho Ji, Stuart Spencer, Tapashi Dalvi, Haiyi Jiang, Jonathan W. Goldman
Publié 2022Artigo -
6
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN par Luis Paz‐Ares, Y Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, E. Musso, Libor Havel, Igor Bondarenko, György Losonczy, Nikolay Conev, Helen Mann, Tapashi Dalvi, Haiyi Jiang, Jonathan W. Goldman
Publié 2022Artigo -
7
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden par Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Nikolay Conev, Igor Bondarenko, Libor Havel, György Losonczy, Mingchao Xie, Zhongwu Lai, Nadia Godin-Heymann, Helen Mann, Haiyi Jiang, Yashaswi Shrestha, Jonathan W. Goldman
Publié 2023Artigo
Outils de recherche:
Sujets similaires
Cancer
Internal medicine
Medicine
Oncology
Biology
Chemotherapy
Immunotherapy
Confidence interval
Durvalumab
Hazard ratio
Nivolumab
Biochemistry
Cancer research
Colorectal cancer
Etoposide
Gastroenterology
Ipilimumab
Lung cancer
Multivariate analysis
Paleontology
Predictive marker
Stage (stratigraphy)
Tremelimumab
Adjuvant
Adjuvant chemotherapy
Apoptosis
Area under the curve
Breast cancer
Carcinoembryonic antigen
Carcinogenesis